Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumours in many other body sites.
Brachytherapy can be used alone or in combination with other therapies such as surgery, External Beam Radiotherapy (EBRT) and chemotherapy.
Brachytherapy contrasts with unsealed source radiotherapy in which a therapeutic radioisotope is injected into the body to chemically localize to the tissue which requires destruction. It also contrasts to EBRT, in which high-energy x-rays (or occasionally gamma-rays from a radioisotope like cobalt-60) are directed at the tumour from outside the body.
Brachytherapy instead involves the precise placement of short-range radiation-sources (radioisotopes) directly at the site of the cancerous tumour. These are enclosed in a protective capsule or wire which allows the ionizing radiation to escape to treat and kill surrounding tissue, but prevents the charge of radioisotope from moving or disolving in body fluids.
The capsule may be removed later, or (with some radioisotopes) it may be allowed to remain in place. A key feature of brachytherapy is that the irradiation only affects a very localized area around the radiation sources.
Exposure to radiation of healthy tissues further away from the sources is therefore reduced. In addition, if the patient moves or if there is any movement of the tumour within the body during treatment, the radiation sources retain their correct position in relation to the tumour.
These characteristics of brachytherapy provide advantages over EBRT – the tumour can be treated with very high doses of localised radiation, whilst reducing the probability of unnecessary damage to surrounding healthy tissues.
